Cirrhosis and Portal Hypertension

References

1. • D'Amico G.
   • Morabito A.
   • D'Amico M.
   • et al.
   New concepts on the clinical course and stratification of compensated and decompensated cirrhosis.
   Hepatol Int. 2018; 12: 34-43
   View in Article

   • Google Scholar
2. • Ratib S.
   • Fleming K.M.
   • Crooks C.J.
   • et al.
   1- and 5-year survival estimates for people with cirrhosis of the liver in England, 1998–2009: a large population study.
   J Hepatol. 2017; 60: 282-289
   View in Article

   • Google Scholar
3. • Gines P.
   • Quintero E.
   • Arroyo V.
   • et al.
   Compensated cirrhosis: natural history and prognostic factors.
   Hepatology. 1987; 7: 122-128
   View in Article

   • Google Scholar
4. • D’Amico G.
   • Garcia-Tsao G.
   • Pagliaro L.
   Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.
   J Hepatol. 2006; 44: 217-231
   View in Article

   • Google Scholar
5. • Moore K.P.
   • Wong F.
   • Ginès P.
   • et al.
   The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club.
   Hepatology. 2003; 38: 258-266
   View in Article

   • Google Scholar
6. • Arroyo V.
   • Gines P.
   • Gerbes A.L.
   • et al.
   Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.
   Hepatology. 1996; 23: 164-176
   View in Article

   • Google Scholar
7. • European Association for the Study of the Liver
   EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.
   J Hepatol. 2018; 69: 406-460
   View in Article

   • Google Scholar
8. • Salerno F.
   • Borroni G.
   • Moser P.
   • et al.
   Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients.
   Am J Gastroenterol. 1993; 88: 514-519
   View in Article

   • Google Scholar
9. • Tonon M.
   • Piano S.
   • Gambino C.G.
   • et al.
   Outcomes and Mortality of Grade 1 Ascites and Recurrent Ascites in Patients With Cirrhosis.
   Clin Gastroenterol Hepatol. 2021 Feb; 19 (e8): 358-366
   View in Article

   • Google Scholar
10. • Schrier R.W.
    • Arroyo V.
    • Bernardi M.
    • et al.
    Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.
    Hepatology. 1988; 8: 1151-1157
    View in Article

    • Google Scholar
11. • Wiest R.
    • Lawson M.
    • Geuking M.
    Pathological bacterial translocation in liver cirrhosis.
    J Hepatol. 2014; 60: 197-209
    View in Article

    • Google Scholar
12. • Albillos A.
    • Lario M.
    • Álvarez-Mon M.
    Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance.
    J Hepatol. 2014; 61: 1385-1396
    View in Article

    • Google Scholar
13. • Arroyo V.
    • Angeli P.
    • Moreau R.
    • et al.
    The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis.
    J Hepatol. 2021; 74: 670-685
    View in Article

    • Google Scholar
14. • Piano S.
    • Angeli P.
    Bacterial Infections in Cirrhosis as a Cause or Consequence of Decompensation?.
    Clin Liver Dis. 2021; 25: 357-372
    View in Article

    • Google Scholar
15. • Balcar L.
    • Tonon M.
    • Semmler G.
    • et al.
    Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event.
    JHEP Rep. 2022; 4: 100513
    View in Article

    • Google Scholar
16. • Piano S.
    • Tonon M.
    • Vettore E.
    • et al.
    Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis.
    J Hepatol. 2017; 67: 1177-1184
    View in Article

    • Google Scholar
17. • Villanueva C.
    • Albillos A.
    • Genescà J.
    • et al.
    β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
    Lancet. 2019; 393: 1597-1608
    View in Article

    • Google Scholar
18. • de Franchis R.
    • Bosch J.
    • Garcia-Tsao G.
    • et al.
    • Baveno VII Faculty
    Baveno VII - Renewing consensus in portal hypertension.
    J Hepatol. 2022; 76: 959-974
    View in Article

    • Google Scholar
19. • Reynolds T.B.
    • Lieberman F.L.
    • Goodman A.R.
    Advantages of treatment of ascites without sodium restriction and without complete removal of excess fluid.
    Gut. 1978; 19: 549-553
    View in Article

    • Google Scholar
20. • Morando F.
    • Rosi S.
    • Gola E.
    • et al.
    Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: A real-life cross-sectional study.
    Liver Int. 2015; 35: 1508-1515
    View in Article

    • Google Scholar
21. • Angeli P.
    • Fasolato S.
    • Mazza E.
    • et al.
    Combined vs. sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: Results of an open randomised clinical trial.
    Gut. 2010; 59: 98-104
    View in Article

    • Google Scholar
22. • Ginès P.
    • Titó L.
    • Arroyo V.
    • et al.
    Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis.
    Gastroenterology. 1988; 94: 1493-1502
    View in Article

    • Google Scholar
23. • Gines A.
    • Fernandez-Esparrach G.
    • Monescillo A.
    • et al.
    Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis.
    Gastroenterology. 1996; 111: 1002-1010
    View in Article

    • Google Scholar
24. • Bernardi M.
    • Caraceni P.
    • Navickis R.J.
    • et al.
    Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials.
    Hepatology. 2012; 55: 1172-1181
    View in Article

    • Google Scholar
25. • Kim J.J.
    • Tsukamoto M.M.
    • Mathur A.K.
    • et al.
    Delayed paracentesis is associated with increased in-hospital mortality in patients with spontaneous bacterial peritonitis.
    Am J Gastroenterol. 2014; 109: 1436-1442
    View in Article

    • Google Scholar
26. • Salerno F.
    • Cammà C.
    • Enea M.
    • et al.
    Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data.
    Gastroenterology. 2007; 133: 825-834
    View in Article

    • Google Scholar
27. • Bureau C.
    • Thabut D.
    • Oberti F.
    • et al.
    Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.
    Gastroenterology. 2017; 152: 157-163
    View in Article

    • Google Scholar
28. • Bureau C.
    • Thabut D.
    • Jezequel C.
    • et al.
    The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.
    Ann Intern Med. 2021; 174: 633-640
    View in Article

    • Google Scholar
29. • Lepida A.
    • Marot A.
    • Trépo E.
    • et al.
    Systematic review with meta-analysis: Automated low-flow ascites pump therapy for refractory ascites.
    Aliment Pharmacol Ther. 2019; 50: 978-987
    View in Article

    • Google Scholar
30. • Bernardi M.
    • Angeli P.
    • Claria J.
    • et al.
    Albumin in decompensated cirrhosis: new concepts and perspectives.
    Gut. 2020; 69: 1127-1138
    View in Article

    • Google Scholar
31. • Caraceni P.
    • Riggio O.
    • Angeli P.
    • et al.
    Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.
    Lancet. 2018; 391: 2417-2429
    View in Article

    • Google Scholar
32. • Di Pascoli M.
    • Fasolato S.
    • Piano S.
    • et al.
    Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites.
    Liver Int. 2019; 39: 98-105
    View in Article

    • Google Scholar
33. • Solà E.
    • Solé C.
    • Simón-Talero M.
    • et al.
    Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial.
    J Hepatol. 2018; 69: 1250-1259
    View in Article

    • Google Scholar
34. • China L.
    • Freemantle N.
    • Forrest E.
    • et al.
    A randomized trial of albumin infusions in hospitalized patients with cirrhosis.
    N Engl J Med. 2021; 384: 808-817
    View in Article

    • Google Scholar
35. • Piano S.
    • Singh V.
    • Caraceni P.
    • et al.
    Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide.
    Gastroenterology. 2019; 156 (e10): 1368-1380
    View in Article

    • Google Scholar
36. • Fernandez J.
    • Piano S.
    • Bartoletti M.
    • et al.
    Management of bacterial and fungal infections in cirrhosis: the MDRO challenge.
    J Hepatol. 2021; 75: S101-S117
    View in Article

    • Google Scholar
37. • Piano S.
    • Fasolato S.
    • Salinas F.
    • et al.
    The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a randomized, controlled clinical trial.
    Hepatology. 2016; 63: 1299-1309
    View in Article

    • Google Scholar
38. • Sort P.
    • Navasa M.
    • Arroyo V.
    • et al.
    Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis.
    N Engl J Med. 1999; 341: 403-409
    View in Article

    • Google Scholar
39. • Fernandez J.
    • del Arbol L.R.
    • Gomez C.
    • et al.
    Norfloxacin vs ceftriaxone in the pro- phylaxis of infections in patients with advanced cirrhosis and hemorrhage.
    Gastroenterology. 2006; 131: 1049-1056
    View in Article

    • Google Scholar
40. • Angeli P.
    • Gines P.
    • Wong F.
    • et al.
    Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites.
    J Hepatol. 2015; 62: 968-974
    View in Article

    • Google Scholar
41. • Fagundes C.
    • Pepin M.N.
    • Guevara M.
    • et al.
    Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis.
    Hepatol. 2012; 57: 267-273
    View in Article

    • Google Scholar
42. • Gambino C.
    • Piano S.
    • Stenico M.
    • et al.
    Diagnostic and prognostic performance of urinary neutrophil gelatinase-associated lipocalin in patients with cirrhosis and acute kidney injury.
    Hepatology. 2022; https://doi.org/10.1002/hep.32799
    View in Article

    • Google Scholar
43. • Martin-Llahì M.M.
    • Pepin M.N.
    • Guevara M.
    • et al.
    Terlipressin and albumin versus albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
    Gastroenterology. 2008; 134: 1352-1359
    View in Article

    • Google Scholar
44. • Wong F.
    • Pappas S.C.
    • Curry M.P.
    • et al.
    Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
    N Engl J Med. 2021; 384: 818-828
    View in Article

    • Google Scholar
45. • Cavallin M.
    • Kamath P.S.
    • Merli M.
    • et al.
    Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial.
    Hepatology. 2015; 62: 567-574
    View in Article

    • Google Scholar
46. • Singh V.
    • Ghosh S.
    • Singh B.
    • et al.
    Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study.
    J Hepatol. 2012; 56: 1293-1298
    View in Article

    • Google Scholar
47. • Arora V.
    • Maiwall R.
    • Rajan V.
    • et al.
    Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure.
    Hepatology. 2020; 71: 600-610
    View in Article

    • Google Scholar
48. • Piano S.
    • Schmidt H.H.
    • Ariza X.
    • et al.
    Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome.
    Clin Gastroenterol Hepatol. 2018; 16: 1792-1800.e3
    View in Article

    • Google Scholar
49. • Cavallin M.
    • Piano S.
    • Romano A.
    • et al.
    Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study.
    Hepatology. 2016; 63: 983-992
    View in Article

    • Google Scholar
50. • Boyer T.D.
    • Sanyal A.J.
    • Garcia-Tsao G.
    • et al.
    Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1.
    Liver Transpl. 2011; 17: 1328-1332
    View in Article

    • Google Scholar
51. • Piano S.
    • Gambino C.
    • Vettore E.
    • et al.
    Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome.
    Hepatology. 2021; 73: 1909-1919
    View in Article

    • Google Scholar